Employees: 02 (2023.0)Legal category: Société à responsabilité limitée (sans autre indication)Size: PMECreation date: 1994-09-02 (31 years)Status: ActiveBusiness sector: Commerce de détail de produits pharmaceutiques en magasin spécialiséLocation: LODEVE (34700), Herault
SARL PHARMACIE AURIOL-AZOULAI : revenue, balance sheet and financial ratios
SARL PHARMACIE AURIOL-AZOULAI is a French company
founded 31 years ago,
specialized in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé.
Based in LODEVE (34700),
this company of category PME
shows in 2021 a revenue of 1.4 M€.
Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Financial history - SARL PHARMACIE AURIOL-AZOULAI (SIREN 398214114)
Indicator
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
Revenue
N/C
N/C
N/C
N/C
1 439 496 €
N/C
N/C
1 546 155 €
N/C
1 713 237 €
1 782 433 €
1 976 024 €
2 050 443 €
Net income
37 330 €
34 678 €
94 020 €
95 954 €
-40 508 €
-149 258 €
60 327 €
35 744 €
82 211 €
45 620 €
93 154 €
86 841 €
47 245 €
EBITDA
N/C
N/C
N/C
N/C
48 305 €
N/C
N/C
96 610 €
N/C
128 100 €
179 238 €
183 531 €
137 130 €
Net margin
N/C
N/C
N/C
N/C
-2.8%
N/C
N/C
2.3%
N/C
2.7%
5.2%
4.4%
2.3%
Revenue and income statement
In 2025, SARL PHARMACIE AURIOL-AZOULAI generates positive net income of 37 k€. Net income represents the final profit after all expenses (operating, financial, exceptional) and corporate tax. Change over 2013-2025: 47 k€ -> 37 k€.
Net income (2025)
?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax
37 330 €
Loading income statement...
Income statement
Item
Amount
% Revenue
Change
The detailed income statement is not available for this company (simplified accounts or confidential data).
Chart evolution
Show :
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Assets
Loading data...
Item
Gross
Deprec.
Net
%
Change
Assets balance sheet data not available for this company
Liabilities
Loading data...
Item
Year
%
Change
Liabilities balance sheet data not available for this company
Solvency and debt ratios
The debt ratio (= Financial debt / Equity x 100) stands at 196%. Critical situation: debt significantly exceeds equity, severely limiting borrowing capacity and exposing the company to default risk. Financial autonomy (= Equity / Total assets x 100) reaches 30%. The balance between equity and debt is satisfactory.
Debt ratio (2025)
?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low 50-100% : Moderate > 100% : High
196.045%
Financial autonomy (2025)
?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy 20-30% : Average < 20% : Low
30.192%
Asset age ratio (2025)
?
Asset age ratio
Definition
Measures the degree of wear of tangible assets.
Formula
Accumulated depreciation / Gross fixed assets x 100
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Indicator
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Debt ratio
753.748
545.998
426.033
351.124
310.837
300.572
258.207
316.754
349.946
277.43
232.8
214.708
196.045
Financial autonomy
10.621
13.821
17.092
19.068
21.974
23.478
25.594
21.657
19.955
23.855
27.424
29.085
30.192
Repayment capacity
36.899
20.396
17.598
26.839
None
56.18
None
None
-38.818
None
None
None
None
Cash flow / Revenue
2.828%
5.046%
6.128%
3.897%
None%
2.06%
None%
None%
-3.067%
None%
None%
None%
None%
Sector positioning
Debt ratio
196.042025
2023
2024
2025
Q1: 13.7
Med: 49.79
Q3: 129.09
Average
In 2025, the debt ratio of SARL PHARMACIE AURIOL-AZO... (196.04) ranks above the median of the sector. This ratio measures the weight of debt relative to equity. A reduction effort could improve financial strength.
Financial autonomy
30.19%2025
2023
2024
2025
Q1: 33.42%
Med: 53.72%
Q3: 72.08%
Average
In 2025, the financial autonomy of SARL PHARMACIE AURIOL-AZO... (30.2%) ranks below the median of the sector. This ratio represents the share of equity in total financing. An improvement would strengthen the competitive position.
Liquidity ratios
The liquidity ratio (= Current assets / Current liabilities) stands at 75.66. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.
Liquidity ratio (2025)
?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good 1-1.5 : Fair < 1 : Liquidity risk
Visualisation créée via abddaf.fr Sources : INPI & BCE - Retraitements : Ministère de l'économie
Indicator
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Liquidity ratio
74.457
74.927
77.515
61.321
103.614
90.857
88.882
81.734
78.622
78.597
85.299
75.419
75.663
Interest coverage
58.121
46.128
39.168
45.867
None
68.999
None
None
191.846
None
None
None
None
Sector positioning
Liquidity ratio
75.662025
2023
2024
2025
Q1: 131.03
Med: 182.25
Q3: 258.64
Watch
In 2025, the liquidity ratio of SARL PHARMACIE AURIOL-AZO... (75.66) ranks in the bottom 25% of the sector. This ratio measures the ability to cover short-term debt with current assets. A ratio below 1 may signal potential cash flow tensions.
Working capital requirement (WCR) and payment terms
Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments.
Operating WCR (2025)
?
Operating WCR
Definition
Financing requirement generated by the operating cycle (inventory + receivables - trade payables).
Formula
Inventory + Customer receivables - Trade payables
Interpretation
Negative = cash released Positive = financing needed
0 €
Customer credit (2025)
?
Customer credit (days)
Definition
Average payment term granted to customers.
Formula
(Customer receivables / Revenue incl. VAT) x 360
Interpretation
< 45j : Good 45-60j : Average > 60j : Long
0 j
Supplier credit (2025)
?
Supplier credit (days)
Definition
Average payment term obtained from suppliers.
Formula
(Trade payables / Purchases incl. VAT) x 360
Interpretation
The longer the term, the better for cash flow
0 j
Inventory turnover (2025)
?
Inventory turnover (days)
Definition
Average storage duration for goods or materials.
Formula
(Inventory / Cost of goods) x 360
Interpretation
The lower the ratio, the faster the turnover
0 j
WCR and payment terms evolution SARL PHARMACIE AURIOL-AZOULAI
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Indicator
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Operating WCR
199 549 €
210 130 €
260 467 €
206 514 €
0 €
228 460 €
0 €
0 €
169 832 €
0 €
0 €
0 €
0 €
Inventory turnover (days)
29
30
37
34
0
37
0
0
36
0
0
0
0
Customer payment term (days)
8
9
14
12
0
13
0
0
16
0
0
0
0
Supplier payment term (days)
48
60
65
89
0
41
0
0
60
0
0
0
0
Positioning of SARL PHARMACIE AURIOL-AZOULAI in its sector
Comparison with sector Commerce de détail de produits pharmaceutiques en magasin spécialisé
Valuation estimate
Based on 277 transactions of similar company sales
in 2025,
the value of SARL PHARMACIE AURIOL-AZOULAI is estimated at
592 991 €
(range 402 406€ - 930 485€).
This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.
Estimated enterprise value2025
277 transactions
402k€592k€930k€
592 991 €Range: 402 406€ - 930 485€
NAF 5 année 2025
Valuation method used
Net Income Multiple
37 330 €
×
15.9x
=592 991 €
Range: 402 407€ - 930 485€
Only this financial indicator is available for this company.
Valuation evolution
Visualisation creee via abddaf.fr Sources : BODACC & INPI
How is this estimate calculated?
This estimate is based on the analysis of 277 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
Net Income Multiple: Relevant for mature companies with stable results.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Similar companies (Commerce de détail de produits pharmaceutiques en magasin spécialisé)
Compare SARL PHARMACIE AURIOL-AZOULAI with other companies in the same sector:
Frequently asked questions about SARL PHARMACIE AURIOL-AZOULAI
What is the revenue of SARL PHARMACIE AURIOL-AZOULAI ?
The revenue of SARL PHARMACIE AURIOL-AZOULAI in 2021 is 1.4 M€.
Is SARL PHARMACIE AURIOL-AZOULAI profitable?
Yes, SARL PHARMACIE AURIOL-AZOULAI generated a net profit of 37 k€ in 2025.
Where is the headquarters of SARL PHARMACIE AURIOL-AZOULAI ?
The headquarters of SARL PHARMACIE AURIOL-AZOULAI is located in LODEVE (34700), in the department Herault.
Where to find the tax return of SARL PHARMACIE AURIOL-AZOULAI ?
The tax return of SARL PHARMACIE AURIOL-AZOULAI is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
In which sector does SARL PHARMACIE AURIOL-AZOULAI operate?
SARL PHARMACIE AURIOL-AZOULAI operates in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé (NAF code 47.73Z). See the 'Sector positioning' section above to compare the company with its competitors.
Item evolution
Rotate your phone to landscape mode to view the chart